Oxygenation inhibits ovarian tumor growth by downregulating STAT3 and cyclin-D1 expressions

Karuppaiyah Selvendiran1, M Lakshmi Kuppusamy, Shabnam Ahmed

  • 1Department of Internal Medicine, Comprehensive Cancer Center, Ohio State University, Columbus, USA.

Insights

Hyperbaric oxygen therapy significantly reduced ovarian tumor growth by inhibiting signal transducer and activator of transcription 3 (STAT3) activation. This approach shows promise for enhancing cancer treatment outcomes.

Area of Science:

  • Oncology
  • Biomedical Engineering
  • Molecular Biology

Background:

  • Hypoxia is prevalent in solid tumors, hindering chemotherapy and radiation therapy effectiveness.
  • Hypoxia promotes tumor progression and drug resistance by overexpressing signal transducer and activator of transcription 3 (STAT3).

Purpose of the Study:

  • To investigate the inhibitory effect of hyperbaric oxygen (HBO) on STAT3 activation and ovarian tumor growth.
  • To evaluate HBO as a potential therapeutic strategy for ovarian cancer.

Main Methods:

  • Human ovarian cancer xenografts in mice were treated daily with HBO (100% oxygen, 2 atm) for up to 21 days.
  • Tumor volume, body weight, and STAT3 (Tyr 705) activation/cyclin-D1 levels were assessed.
  • Combination therapy with HBO and cisplatin was also evaluated.

Main Results:

  • HBO exposure significantly reduced tumor volume without affecting body weight.
  • HBO treatment led to decreased STAT3 activation and cyclin-D1 protein/mRNA levels.
  • Combined HBO and cisplatin therapy reduced tumor volume but caused significant body weight loss.

Conclusions:

  • Hyperoxia, via HBO, inhibits STAT3 activation, a critical factor in ovarian tumor progression.
  • HBO demonstrates potential as an adjuvant therapy to improve ovarian cancer treatment outcomes.
  • Further clinical investigation is warranted for HBO in ovarian cancer treatment.

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...